NO20033785L - Farmasöytisk formulering - Google Patents

Farmasöytisk formulering

Info

Publication number: NO20033785L
Authority: NO; Norway
Prior art keywords: pharmaceutical formulation; formulation; pharmaceutical
Prior art date: 2001-02-27

Application number

NO20033785A

Other languages

English (en)

Other versions

NO20033785D0 (no

Inventor

Nicola Bateman

Julie Cahill

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-27

Filing date

2003-08-26

Publication date

2003-10-24

2001-02-27 Priority claimed from GB0104749A external-priority patent/GB2372444A/en

2001-07-19 Priority claimed from SE0102572A external-priority patent/SE0102572D0/xx

2003-08-26 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2003-08-26 Publication of NO20033785D0 publication Critical patent/NO20033785D0/no

2003-10-24 Publication of NO20033785L publication Critical patent/NO20033785L/no

Links

239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pain & Pain Management (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20033785A 2001-02-27 2003-08-26 Farmasöytisk formulering NO20033785L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0104749A GB2372444A (en)	2001-02-27	2001-02-27	A pharmaceutical formulation comprising bicalutamide and a hydroxypropylmethylcellulose polymer
SE0102572A SE0102572D0 (sv)	2001-07-19	2001-07-19	Pharmaceutical formulation
PCT/GB2002/000766 WO2002067893A2 (en)	2001-02-27	2002-02-22	Pharmaceutical formulation comprising bicalutamide

Publications (2)

Publication Number	Publication Date
NO20033785D0 NO20033785D0 (no)	2003-08-26
NO20033785L true NO20033785L (no)	2003-10-24

Family

ID=26245766

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20033785A NO20033785L (no)	2001-02-27	2003-08-26	Farmasöytisk formulering

Country Status (22)

Country	Link
US (1)	US20040067257A1 (no)
EP (1)	EP1368001B1 (no)
JP (2)	JP3548566B2 (no)
KR (1)	KR20030077042A (no)
CN (1)	CN1503662A (no)
AR (1)	AR032912A1 (no)
AT (1)	ATE307571T1 (no)
CA (1)	CA2439366A1 (no)
CZ (1)	CZ20032225A3 (no)
DE (1)	DE60206889T2 (no)
EE (1)	EE200300416A (no)
HU (1)	HUP0302847A3 (no)
IL (1)	IL157389A0 (no)
IS (1)	IS6915A (no)
MX (1)	MXPA03007641A (no)
NO (1)	NO20033785L (no)
NZ (1)	NZ527532A (no)
PL (1)	PL365746A1 (no)
RU (1)	RU2003128971A (no)
SK (1)	SK10722003A3 (no)
UY (1)	UY27186A1 (no)
WO (1)	WO2002067893A2 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0103424D0 (sv) *	2001-10-15	2001-10-15	Astrazeneca Ab	Pharmaceutical formulation
SE0103838D0 (sv) *	2001-11-16	2001-11-16	Astrazeneca Ab	Pharmaceutical formulation & product
TWI355276B (en) *	2003-01-14	2012-01-01	Akira Tsuji	Gastrointestinal absorption enhancer mediated by p
US20050008691A1 (en) *	2003-05-14	2005-01-13	Arturo Siles Ortega	Bicalutamide compositions
WO2005074991A1 (ja) *	2004-02-09	2005-08-18	Kabushiki Kaisha Sangi	抗腫瘍剤
KR100539706B1 (ko) *	2005-01-25	2005-12-28	지엘팜텍 주식회사	타크로리무스 및 장용성 고분자를 함유하는 고체분산체
CN101128195A (zh) *	2005-02-23	2008-02-20	阿斯利康(瑞典)有限公司	用于递送增加的稳态血浆水平的比卡鲁胺
US8293274B2 (en) *	2005-04-06	2012-10-23	Kabushiki Kaisha Sangi	Intestinal absorptive anti-tumor agent
US7785629B2 (en) *	2005-06-21	2010-08-31	Helm Ag	Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
JP5052051B2 (ja) *	2006-06-16	2012-10-17	トーアエイヨー株式会社	腸溶性顆粒剤及びその製造方法
US20080045600A1 (en) *	2006-08-17	2008-02-21	Gawande Rahul S	Bicalutamide compositions
WO2008063888A2 (en)	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
US20100190777A1 (en)	2007-07-17	2010-07-29	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
EP2191830A4 (en)	2007-09-21	2011-11-23	Shionogi & Co	SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST
JP5204452B2 (ja) *	2007-10-02	2013-06-05	日医工株式会社	ビカルタミド含有製剤
JP2011503048A (ja) *	2007-11-08	2011-01-27	グラクソグループリミテッド	医薬製剤
HUE027598T2 (en) *	2009-04-03	2016-10-28	Hoffmann La Roche	Propane-1-sulfonic acid {3- [5- (4-chlorophenyl) -1H-pyrrolo [2,3-B] pyridine-3-carbonyl] -2,4-difluorophenyl} amide compositions and their uses
CN101987086B (zh) *	2009-08-03	2012-07-18	北京化工大学	一种超细比卡鲁胺口服片剂及其制备方法
US8329724B2 (en)	2009-08-03	2012-12-11	Hoffmann-La Roche Inc.	Process for the manufacture of pharmaceutically active compounds
ES2633317T3 (es)	2009-11-06	2017-09-20	Plexxikon, Inc.	Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
EP2512448B1 (en)	2009-12-18	2016-07-06	Endotis Pharma	Pharmaceutical oral dosage form containing a synthetic oligosaccharide
CN102525876B (zh) *	2010-12-15	2014-03-12	西安力邦医药科技有限责任公司	阿司匹林固体分散体、其制备方法、药物组合物和用途
CN102552103B (zh) *	2010-12-20	2013-11-20	西安力邦医药科技有限责任公司	拉米夫定固体分散体、其制备方法、药物组合物和用途
MA34948B1 (fr)	2011-02-07	2014-03-01	Plexxikon Inc	Composes et procedes de modulation de kinase, et leurs indications
TWI558702B (zh)	2011-02-21	2016-11-21	普雷辛肯公司	醫藥活性物質的固態形式
US9150570B2 (en)	2012-05-31	2015-10-06	Plexxikon Inc.	Synthesis of heterocyclic compounds
TWI673051B (zh)	2012-09-11	2019-10-01	美商梅維森前列腺療法有限責任公司	恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
US9545407B2 (en) *	2014-08-07	2017-01-17	Pharmacyclics Llc	Formulations of a bruton's tyrosine kinase inhibitor
EA201791222A1 (ru)	2014-12-05	2017-09-29	Арагон Фармасьютикалз, Инк.	Противораковые композиции
US10285948B2 (en)	2014-12-05	2019-05-14	Janssen Pharmaceutica Nv	Anticancer compositions
CN109646404B (zh) *	2016-12-15	2022-10-04	华领医药技术（上海）有限公司	葡萄糖激酶激活剂的口服制剂及其制备方法
WO2020210723A1 (en)	2019-04-11	2020-10-15	R.P. Scherer Technologies, Llc	Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
GB2584341B (en) *	2019-05-31	2023-03-01	Gw Res Ltd	Cannabinoid formulations
US11344526B2 (en)	2020-03-20	2022-05-31	The Regents Of The University Of California	Implantable drug delivery devices for localized drug delivery
EP4100075A4 (en)	2020-03-20	2024-01-31	The Regents of University of California	IMPLANTABLE DRUG RELEASE DEVICES FOR LOCALIZED DRUG RELEASE
US11173291B2 (en) *	2020-03-20	2021-11-16	The Regents Of The University Of California	Implantable drug delivery devices for localized drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE28864T1 (de) *	1982-07-23	1987-08-15	Ici Plc	Amide-derivate.
AU1537292A (en) *	1991-04-16	1992-11-17	Nippon Shinyaku Co. Ltd.	Method of manufacturing solid dispersion
WO1995019770A1 (en) *	1994-01-21	1995-07-27	Sepracor, Inc.	Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US20030059471A1 (en) *	1997-12-15	2003-03-27	Compton Bruce Jon	Oral delivery formulation
CA2443040A1 (en) *	2001-04-02	2002-10-17	Nicola Frances Bateman	Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenyl-sulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
SE0103424D0 (sv) *	2001-10-15	2001-10-15	Astrazeneca Ab	Pharmaceutical formulation
SE0103839D0 (sv) *	2001-11-16	2001-11-16	Astrazeneca Ab	Pharmaceutical formulation & product

2002
- 2002-02-22 AT AT02712105T patent/ATE307571T1/de not_active IP Right Cessation
- 2002-02-22 RU RU2003128971/15A patent/RU2003128971A/ru not_active Application Discontinuation
- 2002-02-22 JP JP2002567261A patent/JP3548566B2/ja not_active Expired - Fee Related
- 2002-02-22 CA CA002439366A patent/CA2439366A1/en not_active Abandoned
- 2002-02-22 SK SK1072-2003A patent/SK10722003A3/sk unknown
- 2002-02-22 MX MXPA03007641A patent/MXPA03007641A/es unknown
- 2002-02-22 IL IL15738902A patent/IL157389A0/xx unknown
- 2002-02-22 CZ CZ20032225A patent/CZ20032225A3/cs unknown
- 2002-02-22 EE EEP200300416A patent/EE200300416A/xx unknown
- 2002-02-22 US US10/468,276 patent/US20040067257A1/en not_active Abandoned
- 2002-02-22 CN CNA028087356A patent/CN1503662A/zh active Pending
- 2002-02-22 EP EP02712105A patent/EP1368001B1/en not_active Expired - Lifetime
- 2002-02-22 WO PCT/GB2002/000766 patent/WO2002067893A2/en not_active Ceased
- 2002-02-22 NZ NZ527532A patent/NZ527532A/xx unknown
- 2002-02-22 KR KR10-2003-7011178A patent/KR20030077042A/ko not_active Withdrawn
- 2002-02-22 DE DE60206889T patent/DE60206889T2/de not_active Expired - Fee Related
- 2002-02-22 PL PL02365746A patent/PL365746A1/xx not_active Application Discontinuation
- 2002-02-22 HU HU0302847A patent/HUP0302847A3/hu unknown
- 2002-02-26 UY UY27186A patent/UY27186A1/es not_active Application Discontinuation
- 2002-02-27 AR ARP020100712A patent/AR032912A1/es not_active Application Discontinuation
2003
- 2003-08-15 IS IS6915A patent/IS6915A/is unknown
- 2003-08-26 NO NO20033785A patent/NO20033785L/no not_active Application Discontinuation
2004
- 2004-02-18 JP JP2004041583A patent/JP2004143185A/ja active Pending

Also Published As

Publication number	Publication date
ATE307571T1 (de)	2005-11-15
WO2002067893A3 (en)	2003-01-16
EE200300416A (et)	2003-12-15
DE60206889D1 (de)	2005-12-01
RU2003128971A (ru)	2005-03-10
AR032912A1 (es)	2003-12-03
PL365746A1 (en)	2005-01-10
JP2004143185A (ja)	2004-05-20
CN1503662A (zh)	2004-06-09
NZ527532A (en)	2004-12-24
KR20030077042A (ko)	2003-09-29
WO2002067893A2 (en)	2002-09-06
DE60206889T2 (de)	2006-07-27
JP3548566B2 (ja)	2004-07-28
UY27186A1 (es)	2002-09-30
SK10722003A3 (sk)	2004-02-03
US20040067257A1 (en)	2004-04-08
HUP0302847A3 (en)	2005-05-30
MXPA03007641A (es)	2003-12-04
NO20033785D0 (no)	2003-08-26
CA2439366A1 (en)	2002-09-06
JP2004521918A (ja)	2004-07-22
EP1368001A2 (en)	2003-12-10
IL157389A0 (en)	2004-05-12
IS6915A (is)	2003-08-15
CZ20032225A3 (cs)	2003-11-12
HUP0302847A2 (hu)	2003-12-29
EP1368001B1 (en)	2005-10-26

Legal Events

Date	Code	Title	Description
2006-10-02	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20033384D0 (no)	2003-07-29	Farmasöytisk formulering
NO20033785D0 (no)	2003-08-26	Farmasöytisk formulering
NO20033556L (no)	2003-10-09	Farmasöytiske formuleringer
ITTO20010008A0 (it)	2001-01-10	Formulazione farmaceutica
FI20011478A0 (fi)	2001-07-05	Farmaseuttinen koostumus
PT1501534E (pt)	2006-09-29	Formulacoes farmaceuticas
PL367180A1 (pl)	2005-02-21	Trwała kompozycja farmaceutyczna
NO20035627D0 (no)	2003-12-15	Farmasöytisk formulering
EE200300589A (et)	2004-02-16	Ravimkoostised
FI20022128A0 (fi)	2002-12-03	Farmaseuttinen koostumus
NO20042502L (no)	2004-08-09	Farmasoytisk formulering omfattende bicalutamid
NO20041485L (no)	2004-04-13	Farmasoytisk formulering omfattende (R)-bicalutamid
DE10291905D2 (de)	2004-05-27	Pharmazeutische Zusammensetzung
NO20015534D0 (no)	2001-11-12	Farmasöytisk blandeapparat
EE200300465A (et)	2003-12-15	Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
DE10107261B4 (de)	2005-03-10	Pharmazeutische Zusammensetzung
NO20041236L (no)	2004-03-24	Farmasoytisk formulering
SE0101171D0 (sv)	2001-04-02	Pharmaceutical formulation
SE0102572D0 (sv)	2001-07-19	Pharmaceutical formulation
SE0101326D0 (sv)	2001-04-12	Pharmaceutical formulation
SE0103565D0 (sv)	2001-10-25	Pharmaceutical formulation
SE0101325D0 (sv)	2001-04-12	Pharmaceutical formulation
SE0102957D0 (sv)	2001-09-04	Pharmaceutical formulation
SE0102069D0 (sv)	2001-06-21	Pharmaceutical formulation
EP1413314A4 (en)	2004-12-22	MEDICAL COMPOSITIONS